Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 2
1961 4
1962 3
1965 1
1967 2
1968 3
1969 3
1970 4
1971 13
1972 12
1973 13
1974 11
1975 13
1976 10
1977 16
1978 10
1979 8
1980 10
1981 8
1982 8
1983 3
1984 11
1985 9
1986 14
1987 5
1988 18
1989 8
1990 11
1991 15
1992 8
1993 11
1994 14
1995 23
1996 12
1997 18
1998 22
1999 22
2000 26
2001 28
2002 41
2003 34
2004 36
2005 42
2006 64
2007 58
2008 86
2009 87
2010 63
2011 65
2012 78
2013 74
2014 71
2015 69
2016 80
2017 93
2018 54
2019 62
2020 67
2021 60
2022 41
2023 39
2024 52
2025 43
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,705 results

Results by year

Filters applied: . Clear all
Page 1
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ, Storm MRO, Pereira Ribeiro J, Skoog M, Groth C, Callesen HE, Schaug JP, Darling Rasmussen P, Huus CL, Zwi M, Kirubakaran R, Simonsen E, Gluud C. Storebø OJ, et al. Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD009885. doi: 10.1002/14651858.CD009885.pub3. Cochrane Database Syst Rev. 2023. Update in: Cochrane Database Syst Rev. 2025 Dec 4;12:CD009885. doi: 10.1002/14651858.CD009885.pub4. PMID: 36971690 Free PMC article. Updated.
Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study.
Man KKC, Häge A, Banaschewski T, Inglis SK, Buitelaar J, Carucci S, Danckaerts M, Dittmann RW, Falissard B, Garas P, Hollis C, Konrad K, Kovshoff H, Liddle E, McCarthy S, Neubert A, Nagy P, Rosenthal E, Sonuga-Barke EJS, Zuddas A, Wong ICK, Coghill D; ADDUCE Consortium. Man KKC, et al. Lancet Psychiatry. 2023 May;10(5):323-333. doi: 10.1016/S2215-0366(23)00042-1. Epub 2023 Mar 20. Lancet Psychiatry. 2023. PMID: 36958362
Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence.
Krinzinger H, Hall CL, Groom MJ, Ansari MT, Banaschewski T, Buitelaar JK, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Falissard B, Garas P, Inglis SK, Kovshoff H, Kochhar P, McCarthy S, Nagy P, Neubert A, Roberts S, Sayal K, Sonuga-Barke E, Wong ICK, Xia J, Zuddas A, Hollis C, Konrad K, Liddle EB; ADDUCE Consortium. Krinzinger H, et al. Neurosci Biobehav Rev. 2019 Dec;107:945-968. doi: 10.1016/j.neubiorev.2019.09.023. Epub 2019 Sep 20. Neurosci Biobehav Rev. 2019. PMID: 31545988 Free article. Review.
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C. Storebø OJ, et al. Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD009885. doi: 10.1002/14651858.CD009885.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2023 Mar 27;3:CD009885. doi: 10.1002/14651858.CD009885.pub3. PMID: 26599576 Free PMC article. Updated.
Efficacy and safety of methylphenidate and behavioural parent training for children aged 3-5 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial.
Sugaya LS, Salum GA, de Sousa Gurgel W, de Morais EM, Del Prette G, Pilatti CD, Dalmaso BB, Leibenluft E, Rohde LA, Polanczyk GV. Sugaya LS, et al. Lancet Child Adolesc Health. 2022 Dec;6(12):845-856. doi: 10.1016/S2352-4642(22)00279-6. Epub 2022 Oct 26. Lancet Child Adolesc Health. 2022. PMID: 36306807 Free PMC article. Clinical Trial.
Methylphenidate Induced Ecchymosis.
Şahan E, Boylu ME. Şahan E, et al. Psychiatr Danub. 2021 Spring;33(1):65-66. doi: 10.24869/psyd.2021.65. Psychiatr Danub. 2021. PMID: 33857043 Free article. No abstract available.
Methylphenidate and Short-Term Cardiovascular Risk.
Garcia-Argibay M, Bürkner PC, Lichtenstein P, Zhang L, D'Onofrio BM, Andell P, Chang Z, Cortese S, Larsson H. Garcia-Argibay M, et al. JAMA Netw Open. 2024 Mar 4;7(3):e241349. doi: 10.1001/jamanetworkopen.2024.1349. JAMA Netw Open. 2024. PMID: 38446477 Free PMC article.
Stimulants.
Childress AC. Childress AC. Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):373-392. doi: 10.1016/j.chc.2022.03.001. Epub 2022 May 11. Child Adolesc Psychiatr Clin N Am. 2022. PMID: 35697391 Review.
1,705 results